Early detection of elevated liver function test in drug-resistant tuberculosis with short term therapy and individual therapy
- pdf |
- DOI: https://doi.org/10.15562/bmj.v11i1.3113 |
- Published: 2022-04-20
Open Access & Peer Reviewed Multidisciplinary
Journal of Medical Sciences
Journal of Medical Sciences
Abstract
Introduction: Tuberculosis (TB) treatment consists of more than one drug to achieve goal treatment. Hepatotoxicity is a form of side effect that causes the termination of TB treatment or regimen changes due to treatment failure, relapse, and drug resistance. Hepatotoxicity may increase the problem, covering more than 7% of all side effects. DILI is also one of the concerns in the treatment of TB. The objective of this study to assess the role of risk factor in the hepatotoxicity during drug-resistant TB treatment and investigate the time of onset hepatotoxicity during drug-resistant TB treatment.
Methods: The research method was retrospective study. Comprehensive demographic and clinical data, management, and outcome were recorded. Patients who were treated with drug-resistant treatment in Dr. Soetomo General Hospital between January 2018 and January 2020 were enrolled. The statistical method used SPSS ver 16.0. A total sample of 129 patients met the inclusion and exclusion criteria.
Results: Prevalence of hepatotoxic side effects was 54 cases. A total of 2 patients occurred hepatotoxicity in the first 2 weeks, and 52 patients developed hepatotoxicity in the late 2 weeks. There was one risk factor influencing the hepatotoxic side effects of drug-resistant Tuberculosis treatment. The history of alcohol consumption the only one risk factor (OR=3,182; 95% Cl=0,120-9,927.
Conclusion: Hepatotoxicity is a common problem among patients during Antituberculosis Treatment, especially on drug-resistant Tuberculosis in our population. Early detection not only reduces the risk of developing hepatic injury but also prevents mortality.
References
- WHO. Tuberculosis [Internet]. 2021. p. 1. Available from: https://www.who.int/news-room/fact-sheets/detail/tuberculosis
- Ramappa V, Aithal GP. Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management. J Clin Exp Hepatol [Internet]. 2013;3(1):37–49. Available from: http://dx.doi.org/10.1016/j.jceh.2012.12.001
- Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J. 1996;9(10):2026–30.
- Ostapowicz G, Fontana RJ, Schiødt F V, Larson A, Davern TJ, Han SHB, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002 Dec;137(12):947–54.
- Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011 Jun;89(6):806–15.
- Babalık A, Arda H, Bakırcı N, Ağca S, Oruç K, Kızıltaş S, et al. Management of and risk factors related to hepatotoxicity during tuberculosis treatment. Tuberk Toraks. 2012;60(2):136–44.
- Tostmann A. Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review. 2008;23:pp. 192–202.
- Ramappa V, and Aithal GP. Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management. Journal of Clinical and Experimental Hepatology. Elsevier Ltd. 2013;3(1):pp. 37–49.
- Saukkonen J, Cohn D, Jasmer R, Schenker S, Jereb J, et al. An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy. American Journal of Respiratory and Critical Care Medicine. 2006;174(8):pp.935-952.
- Senousy BE, Belal SI, Draganov PV. Hepatotoxic effects of therapies for Tuberculosis, Nat. Rev. Gastroenterol. Hepatol. 2010;7:543–556.
How to Cite
Abdul Azis, F. D., & Nurlaila, H. (2022). Early detection of elevated liver function test in drug-resistant tuberculosis with short term therapy and individual therapy. Bali Medical Journal, 11(1), 324–327. https://doi.org/10.15562/bmj.v11i1.3113
